Fierce Biotech reported that Juvaris BioTherapeutics has attracted a new investor for its novel adjuvant technology and its lead candidate JVRS-100. This continues the interest shown in the adjuvant area with the resurgence of the vaccine market.
GEN recently noted this trend as well in its review of the vaccine market. Several newer adjuvants that are designed to produce greater immunogenicity than the more traditonal aluminum salts are making inroads. These include immunostimulators and microparticulate carriers, and may consist of more novel raw materials like cationionic lipids, squalene, and saponin as examples. Several new adjuvants are in clinical trials.
Posted by Bruce Lehr Jan 27, 2010